Bellus Health Inc. - a GSK company
Pre-Approval PRO BETASlowing Activity
No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 7/9/2024
Pipeline by Phase
Therapeutic Focus
Clinical Trials (14)
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Started: 12/5/2022
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Started: 10/25/2022
A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis
Started: 12/9/2020
Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Started: 12/7/2020
A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough
Started: 7/10/2019
A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes
Started: 4/1/2008
A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age
Started: 2/2/2024
Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation
Started: 10/7/2022
Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant
Started: 7/26/2023
A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants
Started: 7/9/2024
Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant
Started: 6/21/2023
Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects
Started: 8/6/2021
Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937
Started: 8/25/2020
BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect
Started: 7/9/2018